Reporter Glenn Greenwald, who has been in the news recently for disseminating the whistle-blower and former CIA employee Edward Snowden’s information on the US’s mass surveillance program has left The Guardian where his initial articles appeared
Reporter Glenn Greenwald, who has been in the news recently for disseminating the whistle-blower and former CIA employee Edward Snowden’s information on the US’s mass surveillance program has left The Guardian where his initial articles appeared. Along with filmmaker Laura Poitras (also covering the Snowden story) and Jeremy Scahill, Greenwald is joining up with Pierre Omidyar, one of the founders of Ebay, who has announced that he’s funding a journalism project with $250 million dollars in seed money.
It’s intriguing media news in a world where the line between editorial and advertising is increasingly blurred, and publications are dying off like flies.
Omidyar intends to publish progressive, long-form, investigative stories written by the country’s best specialist writers on a variey of different subjects.
Whose on his dream team? He published his wish list on Tuesday on Opednews.com.
And who would he pick to cover the pharma industry? Martha Rosenberg, he says, “who does great investigative reporting on food and drug safety and Big Pharma and Big Agra.”
Her work is certainly provocative and hardhitting, and sometimes loads of fun to read, but is it fair?
Writing for a variey of publications, here are just a few of her recent titles:
6 New Ways Big Pharma Is Scheming to Make Billions at the Expense of Your Health
Big Pharma Company Mocked Patients Who Got “Jawbone Death” from Drug
How Kids Are Getting Hooked on Pills for Life
You get the idea. My personal point of view is that it’s easy to muckrake, but a lot harder to dig deep to reveal texture and complexity of a topic. But we will wait and see. There’s always room for other voices.
Novel GLP-1 Receptor Agonist Demonstrates Promising Results Treating Patients with Obesity
January 21st 2025Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a half-life of up to 60 hours, and superior pharmacokinetic properties compared to other oral GLP-1 receptor agonists.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
FDA Approves Amgen’s Lumakras Plus Vectibix for KRAS G12C-Mutated Metastatic Colorectal Cancer
January 20th 2025Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and Vectibix significantly improved progression-free survival in patients with KRAS G12C-mutated metastatic colorectal cancer.